SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19 : The International Study of Inflammation in COVID-19
© 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC..
Severe coronavirus disease 2019 (COVID-19) is a hyperinflammatory syndrome. The biomarkers of inflammation best suited to triage patients with COVID-19 are unknown. We conducted a prospective multicenter observational study of adult patients hospitalized specifically for COVID-19 from February 1, 2020 to October 19, 2022. Biomarkers measured included soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein, interleukin-6, procalcitonin, ferritin, and D-dimer. In-hospital outcomes examined include death and the need for mechanical ventilation. Patients admitted in the United States (US, n = 1962) were used to compute area under the curves (AUCs) and identify biomarker cutoffs. The combined European cohorts (n = 1137) were used to validate the biomarker cutoffs. In the US cohort, 356 patients met the composite outcome of death (n = 197) or need for mechanical ventilation (n = 290). SuPAR was the most important predictor of the composite outcome and had the highest AUC (0.712) followed by CRP (0.642), ferritin (0.619), IL-6 (0.614), D-dimer (0.606), and lastly procalcitonin (0.596). Inclusion of other biomarkers did not improve discrimination. A suPAR cutoff of 4.0 ng/mL demonstrated a sensitivity of 95.4% (95% CI: 92.4%-98.0%) and negative predictive value (NPV) of 92.5% (95% CI: 87.5%-96.9%) for the composite outcome. Patients with suPAR < 4.0 ng/mL comprised 10.6% of the cohort and had a 0.8% probability of the composite outcome. Applying this cutoff to the validation cohort yielded a sensitivity of 93.8% (90.4%-96.7%) and NPV of 95.5% (93.1%-97.8%) for the composite outcome. Among commonly measured biomarkers, suPAR offered stronger discriminatory ability and may be useful in triaging low-risk patients with COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Journal of medical virology - 96(2024), 1 vom: 31. Jan., Seite e29389 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.01.2024 Date Revised 02.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.29389 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36726417X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36726417X | ||
| 003 | DE-627 | ||
| 005 | 20240202232146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.29389 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM36726417X | ||
| 035 | |a (NLM)38235904 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vasbinder, Alexi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19 |b The International Study of Inflammation in COVID-19 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2024 | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. | ||
| 520 | |a Severe coronavirus disease 2019 (COVID-19) is a hyperinflammatory syndrome. The biomarkers of inflammation best suited to triage patients with COVID-19 are unknown. We conducted a prospective multicenter observational study of adult patients hospitalized specifically for COVID-19 from February 1, 2020 to October 19, 2022. Biomarkers measured included soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein, interleukin-6, procalcitonin, ferritin, and D-dimer. In-hospital outcomes examined include death and the need for mechanical ventilation. Patients admitted in the United States (US, n = 1962) were used to compute area under the curves (AUCs) and identify biomarker cutoffs. The combined European cohorts (n = 1137) were used to validate the biomarker cutoffs. In the US cohort, 356 patients met the composite outcome of death (n = 197) or need for mechanical ventilation (n = 290). SuPAR was the most important predictor of the composite outcome and had the highest AUC (0.712) followed by CRP (0.642), ferritin (0.619), IL-6 (0.614), D-dimer (0.606), and lastly procalcitonin (0.596). Inclusion of other biomarkers did not improve discrimination. A suPAR cutoff of 4.0 ng/mL demonstrated a sensitivity of 95.4% (95% CI: 92.4%-98.0%) and negative predictive value (NPV) of 92.5% (95% CI: 87.5%-96.9%) for the composite outcome. Patients with suPAR < 4.0 ng/mL comprised 10.6% of the cohort and had a 0.8% probability of the composite outcome. Applying this cutoff to the validation cohort yielded a sensitivity of 93.8% (90.4%-96.7%) and NPV of 95.5% (93.1%-97.8%) for the composite outcome. Among commonly measured biomarkers, suPAR offered stronger discriminatory ability and may be useful in triaging low-risk patients with COVID-19 | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C-reactive protein | |
| 650 | 4 | |a CRP | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SuPAR | |
| 650 | 4 | |a infection | |
| 650 | 4 | |a interleukin-6 | |
| 650 | 4 | |a risk prediction | |
| 650 | 4 | |a soluble urokinase plasminogen activator receptor | |
| 650 | 4 | |a triage | |
| 650 | 7 | |a Receptors, Urokinase Plasminogen Activator |2 NLM | |
| 650 | 7 | |a Procalcitonin |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Ferritins |2 NLM | |
| 650 | 7 | |a 9007-73-2 |2 NLM | |
| 700 | 1 | |a Padalia, Kishan |e verfasserin |4 aut | |
| 700 | 1 | |a Pizzo, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Kristen |e verfasserin |4 aut | |
| 700 | 1 | |a Catalan, Tonimarie |e verfasserin |4 aut | |
| 700 | 1 | |a Presswalla, Feriel |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Ismail, Anis |e verfasserin |4 aut | |
| 700 | 1 | |a Hutten, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yiyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Blakely, Pennelope |e verfasserin |4 aut | |
| 700 | 1 | |a Azam, Tariq U |e verfasserin |4 aut | |
| 700 | 1 | |a Berlin, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Feroze, Rafey |e verfasserin |4 aut | |
| 700 | 1 | |a Launius, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Meloche, Chelsea |e verfasserin |4 aut | |
| 700 | 1 | |a Michaud, Erinleigh |e verfasserin |4 aut | |
| 700 | 1 | |a O'Hayer, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Shadid, Husam R |e verfasserin |4 aut | |
| 700 | 1 | |a Rasmussen, Line Jee Hartmann |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Donald A |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Lili |e verfasserin |4 aut | |
| 700 | 1 | |a Banerjee, Mousumi |e verfasserin |4 aut | |
| 700 | 1 | |a Murthy, Venkatesh |e verfasserin |4 aut | |
| 700 | 1 | |a Loosen, Sven H |e verfasserin |4 aut | |
| 700 | 1 | |a Chalkias, Athanasios |e verfasserin |4 aut | |
| 700 | 1 | |a Tacke, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Reiser, Jochen |e verfasserin |4 aut | |
| 700 | 1 | |a Giamarellos-Bourboulis, Evangelos J |e verfasserin |4 aut | |
| 700 | 1 | |a Eugen-Olsen, Jesper |e verfasserin |4 aut | |
| 700 | 1 | |a Pop-Busui, Rodica |e verfasserin |4 aut | |
| 700 | 1 | |a Hayek, Salim S |e verfasserin |4 aut | |
| 700 | 0 | |a ISIC investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 96(2024), 1 vom: 31. Jan., Seite e29389 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2024 |g number:1 |g day:31 |g month:01 |g pages:e29389 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.29389 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2024 |e 1 |b 31 |c 01 |h e29389 | ||